Related Experiment Video
Updated: Jul 7, 2025
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack
Luigi Cerbone1, Sara Orecchia2, Pietro Bertino1
1Mesothelioma Unit, SS Antonio e and Biagio Hospital, 15121 Alessandria, Italy.
Cancers
|December 23, 2023
Summary
Next-generation sequencing (NGS) reveals mesothelioma
Area of Science:
- Oncology
- Genomics
- Cancer Research
Background:
- Mesothelioma is a rare cancer linked to asbestos exposure with poor prognosis.
- Limited therapeutic options exist for mesothelioma patients.
- Genomic studies reveal frequent alterations in tumor suppressor genes.
Purpose of the Study:
- To review next-generation sequencing (NGS) applications in mesothelioma.
- To explore targeted therapy strategies for mesothelioma based on NGS findings.
Main Methods:
- Review of existing next-generation sequencing (NGS) studies on mesothelioma.
- Analysis of genomic landscapes and identified mutations.
Main Results:
- Mesothelioma exhibits frequent genomic aberrations, particularly loss-of-function mutations in tumor suppressor genes (BAP1, CDKN2A, NF2, SETD2, TP53).
- A small subset (1-2%) of mesothelioma cases may have actionable oncogene mutations.
- Targeted drug efficacy for these specific alterations remains largely unproven.
Conclusions:
- NGS provides a comprehensive view of mesothelioma's genomic profile.
- Targeted therapy guided by NGS holds potential for mesothelioma treatment.
- Further research is needed to validate targeted therapies for mesothelioma.
